Abiopharma

🔍 Hartwick Kenneth Michael (Executive)

Company: MYR GROUP INC. (MYRG)

Report Date: 2026-04-23

Detailed Transactions and Holdings:

• Acquired 1,657 shares of Common Stock (Direct)
  Date: 2025-04-24 | Code: M | equity_swap_involved: false | shares_owned_after: 23,917.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 591 shares of RESTRICTED STOCK UNIT (Derivative)
  Date: 2026-04-23 | Code: A | equity_swap_involved: false | shares_owned_after: 591.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Sold 1,657 shares of RESTRICTED STOCK UNIT (Derivative)
  Date: 2026-04-24 | Code: M | Expires: 2026-04-24 | Exercise: 2026-04-24 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: These Restricted Stock Units, which were awarded on April 24, 2025 pursuant to the Issuer's 2017 Long-Term Incentive Plan, vested on April 24, 2026 and were settled in shares of the Issuer's common stock on a one-for-one basis. The payment of such shares has been deferred in accordance with the Reporting Person's election pursuant to the Issuer's non-employee director deferral program.
• F2: Each Restricted Stock Unit, awarded pursuant to the Issuer's 2017 Long-Term Incentive Plan, represents a contingent right to receive one share of the Issuer's common stock. Restricted Stock Units will be converted into 591 shares of the Issuer's common stock on April 23, 2027, and the payment of such shares will be deferred in accordance with the Reporting Person's election pursuant to the Issuer's non-employee director deferral program.